Biology subjects

Hatch, K. S.

Publications and source records attributed to Hatch, K. S..

5 recordsLinked to original sources

bioRxiv2026

Conformation governs cellular behaviors of LRRK2 Parkinson's disease variants

Gain-of-function of leucine-rich repeat kinase 2 (LRRK2) is a common cause of Parkinson's disease (PD). In its autoinhibited state, the leucine-rich repeats of LRRK2 block the kinase active site, preventing substrate phosphorylation. Displacing the repeats ('unlatching') primes LRRK2 for activity. Preferential unlatching causes increased substrate phosphorylation of the PD allele LRRK2[R1441H], but not LRRK2[G2019S]. Here, we define a large class of PD-associated 'unlatching' mutations based on their effect on LRRK2 conformation. Unlatching mutants show increased localization to membranes, the site of LRRK2's Rab substrates. Unlatching mutants are also characterized by decreased LRRK2 S935 phosphorylation, which we define as a biomarker of conformation. This framework resolves the mechanism of variants such as I2020T, which structural studies could not predict. Overall, we establish unlatching as a unifying mechanism for most PD-linked variants and describe measurable readouts for identifying LRRK2-driven disease.

cell biology↗

bioRxiv2026

The structural basis for LRRK2's activation and autoinhibition

Mutations in Leucine-Rich Repeat Kinase 2 (LRRK2) are the second most common cause of autosomal-dominant Parkinsons disease (PD), and increased LRRK2 kinase activity is also observed in idiopathic PD, making LRRK2 a major actionable therapeutic target. LRRK2 is a 286-kDa multidomain enzyme containing a Ras-like GTPase (ROC) and a kinase domain. Using cryo-EM, biochemical reconstitution, and cell-based assays, we show that the ROC GTPase governs switching between autoinhibited and active states: GTP binding promotes activation, whereas GDP binding enforces autoinhibition. Two common PD-linked mutations, G2019S and R1441C/G/H, activate LRRK2 through distinct structural mechanisms, revealing genotype-specific routes to dysregulation. These findings provide a unified framework for understanding LRRK2 regulation with broad therapeutic implications. Stabilizing the GDP-bound state may inhibit LRRK2 by maintaining autoinhibition, whereas promoting the GTP-bound state could be advantageous in specific cellular contexts, such as the lung, where increased LRRK2 kinase activity may play protective or regulatory roles.

neuroscience↗

bioRxiv2023

Development of LRRK2 designed ankyrin-repeat proteins

Leucine rich repeat kinase 2 (LRRK2) is a large multidomain protein containing two catalytic domains, a kinase and a GTPase, as well protein interactions domains, including a WD40 domain. The association of increased LRRK2 kinase activity with both the familial and sporadic forms of Parkinsons disease (PD) has led to intense interest in determining its cellular function. However, small molecule probes that can bind to LRRK2 and report on or affect its activity are needed. Here, we identified a series of high-affinity LRRK2-binding designed ankyrin-repeat proteins (DARPins). One of these DARPins (E11) bound to the LRRK2 WD40 domain with high affinity. LRRK2 bound to DARPin E11 showed improved behavior on cryo-EM grids, resulting in higher resolution LRRK2 structures. DARPin E11 did not affect the catalytic activity of a truncated form of LRRK2 in vitro but decreased the phosphorylation of Rab8A, a LRRK2 substrate, in cells. We also found that DARPin E11 disrupts the formation of microtubule-associated LRRK2 filaments in cells, which are known to require WD40-based dimerization. Thus, DARPin E11 is a new tool to explore the function and dysfunction of LRRK2 and guide the development of LRRK2 kinase inhibitors that target the WD40 domain instead of the kinase.

biochemistry↗

bioRxiv2023

APOE4 poses opposite effects of plasma LDL on white matter integrity in older adults

INTRODUCTIONAPOE4 is a strong genetic risk factor of Alzheimers disease and is associated with changes in metabolism. However, the interactive relationship between APOE4 and plasma metabolites on the brain remains largely unknown. MEHODSIn the UK Biobank, we investigated the moderation effects of APOE4 on the relationship between 249 plasma metabolites derived from nuclear magnetic resonance spectroscopy on whole-brain white matter integrity, measured by fractional anisotropy using diffusion magnetic resonance imaging. RESULTSThe increase in the concentration of metabolites, mainly LDL and VLDL, is associated with a decrease in white matter integrity (b= -0.12, CI= [-0.14, -0.10]) among older APOE4 carriers, whereas an increase (b= 0.05, CI= [0.04, 0.07]) among non-carriers, implying a significant moderation effect of APOE4 (b= -0.18, CI= [-0.20,-0.15]). DISCUSSIONThe results suggest that lipid metabolism functions differently in APOE4 carriers compared to non-carriers, which may inform the development of targeted interventions for APOE4 carriers to mitigate cognitive decline.

neuroscience↗

bioRxiv2020

White matter brain aging In Relationship to Schizophrenia and Its Cognitive Deficit

We hypothesized that cerebral white matter deficits in schizophrenia (SZ) are driven in part by accelerated white matter aging and are associated with cognitive deficits. We used machine learning model to predict individual age from diffusion tensor imaging features and calculated the delta age ({Delta}age) as the difference between predicted and chronological age. Through this approach, we translated multivariate white matter imaging features into an age-scaled metric and used it to test the temporal trends of accelerated aging-related white matter deficit in SZ and its association with the cognition. Followed feature selection, a machine learning model was trained with fractional anisotropy values in 34 of 43 tracts on a training set consisted of 107 healthy controls (HC). The brain age of 166 SZs and 107 HCs in the testing set were calculated using this model. Then, we examined the SZ-HC group effect on {Delta}age and whether this effect was moderated by chronological age using the regression spline model. The results showed that {Delta}age was significantly elevated in the age >30 group in patients (p < 0.001) but not in age [<=] 30 group (p = 0.364). {Delta}age in patients was significantly and negatively associated with both working memory ({beta} = -0.176, p = 0.007) and processing speed ({beta} = -0.519, p = 0.035) while adjusting sex and chronological age. Overall, these findings indicate that the {Delta}age is elevated in SZs and become significantly from middle life stage; the increase of {Delta}age in SZs is associated with the decline neurocognitive performance.

neuroscience↗